Business
Allergy Therapeutics to Present at Jefferies 2017
Allergy Therapeutics to Present at Jefferies 2017.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 2495W Allergy Therapeutics PLC 13 November 2017 \n\n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nAllergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference \n \n \n13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that Manuel Llobet, Chief Executive Officer, will be presenting at the Jefferies 2017 Healthcare Conference in London, on Wednesday 15 November at 13:20 GMT. \n \n \n- ENDS -\n \nFor further information, please contact:\n \nAllergy Therapeutics\n+44 (0) 1903 845 820\nManuel Llobet, Chief Executive Officer\nNick Wykeman, Finance Director\n \nPanmure Gordon\n+44 (0) 20 7886 2500\nFreddy Crossley / Duncan Monteith, Corporate Finance\nTom Salvesen, Corporate Broking\n \nConsilium Strategic Communications\n+44 20 3709 5700\nMary-Jane Elliott / Ivar Milligan / Philippa Gardner/ Rosie Phillips \[email protected]\n \nNotes for editors:\n \nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.\n \nFormed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com. \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NRAEADFAF...